Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 39 clinical trials
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

solid tumor
ROS1
crizotinib
NTRK
targeted therapy
  • 15 views
  • 14 May, 2022
  • 10 locations
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations …

ROS1
cancer
solid tumour
measurable disease
lymphoma
  • 0 views
  • 26 Mar, 2022
  • 26 locations
Vinorelbine for Recurrent ALCL-2017

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.

stem cell transplantation
cancer
  • 6 views
  • 26 Feb, 2022
  • 1 location
A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with relapsed/refractory anaplastic large cell lymphoma (ALCL) .

  • 0 views
  • 01 Mar, 2022
  • 1 location
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)

The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.

  • 0 views
  • 04 May, 2022
  • 1 location
  • 6 views
  • 10 May, 2022
  • 5 locations
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory

  • 6 views
  • 24 Jan, 2021
  • 1 location
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study

anaplastic large cell lymphoma
cancer
b-cell lymphoma
hodgkin's disease
large cell lymphoma
  • 7 views
  • 24 Feb, 2022
  • 1 location
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

The purpose of this study is to test the safety and efficacy of AUTO4 a CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma.

gilbert's syndrome
large cell lymphoma
peripheral t-cell lymphoma
neutrophil count
t-cell lymphoma
  • 44 views
  • 22 Mar, 2022
  • 5 locations
Crizotinib Continuation Clinical Study

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

crizotinib
  • 0 views
  • 24 Mar, 2022
  • 1 location